NeoPharm Past Earnings Performance
Past criteria checks 2/6
NeoPharm has been growing earnings at an average annual rate of 3.6%, while the Personal Products industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 4.7% per year. NeoPharm's return on equity is 13.8%, and it has net margins of 21.3%.
Key information
3.6%
Earnings growth rate
2.6%
EPS growth rate
Personal Products Industry Growth | 3.8% |
Revenue growth rate | 4.7% |
Return on equity | 13.8% |
Net Margin | 21.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Revenue & Expenses Breakdown
How NeoPharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 107,858 | 22,929 | 37,490 | 2,838 |
31 Mar 24 | 101,735 | 22,516 | 37,305 | 2,690 |
31 Dec 23 | 97,105 | 23,213 | 36,276 | 2,647 |
30 Sep 23 | 92,271 | 20,733 | 34,924 | 2,777 |
30 Jun 23 | 89,292 | 19,781 | 34,142 | 2,739 |
31 Mar 23 | 86,272 | 18,912 | 33,087 | 2,805 |
31 Dec 22 | 85,033 | 17,027 | 32,984 | 2,854 |
30 Sep 22 | 86,805 | 18,245 | 34,685 | 2,898 |
30 Jun 22 | 87,424 | 17,370 | 35,790 | 3,043 |
31 Mar 22 | 87,321 | 16,905 | 35,587 | 2,945 |
31 Dec 21 | 87,931 | 17,713 | 36,022 | 2,935 |
30 Sep 21 | 86,802 | 18,207 | 35,087 | 2,764 |
30 Jun 21 | 85,275 | 18,059 | 34,107 | 2,658 |
31 Mar 21 | 85,287 | 18,474 | 34,509 | 2,880 |
31 Dec 20 | 81,625 | 18,131 | 32,991 | 2,802 |
30 Sep 20 | 81,413 | 18,734 | 34,094 | 2,824 |
30 Jun 20 | 82,618 | 19,935 | 33,905 | 2,768 |
31 Mar 20 | 82,680 | 19,901 | 33,407 | 2,602 |
31 Dec 19 | 83,240 | 19,245 | 33,958 | 2,518 |
30 Sep 19 | 79,611 | 18,002 | 31,038 | 2,550 |
30 Jun 19 | 74,863 | 16,675 | 29,562 | 2,659 |
31 Mar 19 | 69,500 | 15,795 | 27,654 | 2,616 |
31 Dec 18 | 66,275 | 15,370 | 26,275 | 2,576 |
30 Sep 18 | 63,143 | 13,682 | 26,592 | 2,616 |
30 Jun 18 | 60,236 | 13,105 | 25,495 | 2,355 |
31 Mar 18 | 57,175 | 12,514 | 24,577 | 2,257 |
31 Dec 17 | 53,634 | 11,559 | 23,626 | 2,098 |
30 Sep 17 | 49,765 | 9,814 | 23,097 | 2,105 |
30 Jun 17 | 46,739 | 9,365 | 21,372 | 2,068 |
31 Mar 17 | 43,164 | 8,096 | 19,726 | 2,184 |
31 Dec 16 | 42,369 | 7,742 | 19,678 | 2,183 |
30 Sep 16 | 43,097 | 5,955 | 19,902 | 2,206 |
30 Jun 16 | 41,999 | 5,419 | 19,831 | 2,209 |
31 Dec 15 | 35,965 | 3,407 | 17,998 | 1,973 |
30 Sep 13 | 19,350 | 1,475 | 13,933 | 0 |
Quality Earnings: A092730 has a high level of non-cash earnings.
Growing Profit Margin: A092730's current net profit margins (21.3%) are lower than last year (22.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A092730's earnings have grown by 3.6% per year over the past 5 years.
Accelerating Growth: A092730's earnings growth over the past year (15.9%) exceeds its 5-year average (3.6% per year).
Earnings vs Industry: A092730 earnings growth over the past year (15.9%) did not outperform the Personal Products industry 30.2%.
Return on Equity
High ROE: A092730's Return on Equity (13.8%) is considered low.